Certara (CERT)
NASDAQ:CERT
CERT Stock Chart & Stats
$6.10
-$0.37(-3.29%)
At close: 4:00 PM EST
$6.10
-$0.37(-3.29%)
Day’s Range― - ―
52-Week Range$6.02 - $15.38
Previous CloseN/A
Volume176.64K
Average Volume (3M)3.55M
Market Cap
$977.12M
Enterprise Value$799.95M
Total Cash (Recent Filing)$189.39M
Total Debt (Recent Filing)$11.40M
Price to Earnings (P/E)―
Beta1.60
Next Earnings
May 11, 2026EPS Estimate
0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.09
Shares Outstanding159,139,560
10 Day Avg. Volume4,284,619
30 Day Avg. Volume3,553,906
Financial Highlights & Ratios
PEG Ratio10.22
Price to Book (P/B)1.33
Price to Sales (P/S)3.37
P/FCF Ratio14.94
Enterprise Value/Market Cap0.82
Enterprise Value/Revenue1.91
Enterprise Value/Gross Profit3.10
Enterprise Value/Ebitda7.07
Forecast
1Y Price Target
$9.50Price Target Upside55.74% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)0.45
Revenue Forecast (FY)$428.18M
Bulls Say, Bears Say
Bulls Say
Biosimulation Adoption And Cross-sellAnalyst's Buy rating highlights the company's leadership in biosimulation and its ability to cross-sell related software, which could drive broader adoption in drug development and restore software-driven sales growth.
Commercial Leadership And ExecutionNew CEO's commercial experience and a focused plan to sharpen sales execution and deepen customer relationships could improve sales conversion and reaccelerate revenue growth.
Software Revenue ResilienceSoftware outperformance, supported by key products and contributions from recent product acquisitions, bolsters higher-margin revenue and reduces dependence on services.
Bears Say
Enterprise Software Booking WeaknessLarge customer seat reductions for flagship products and timing-related softness in clinical trial tools signal weaker enterprise software bookings and risk to future software revenue momentum.
Guidance And Valuation UncertaintyModest company guidance and analyst target cuts reflect execution uncertainty and could lead to further multiple contraction until growth initiatives demonstrate clearer traction.
Research And Development Investment PressurePlanned investments in research and development and artificial intelligence to support the commercial strategy are expected to compress operating margins despite some offsetting cost savings.
Certara News
CERT FAQ
What was Certara’s price range in the past 12 months?
Certara lowest stock price was $6.02 and its highest was $15.38 in the past 12 months.
What is Certara’s market cap?
Certara’s market cap is $977.12M.
When is Certara’s upcoming earnings report date?
Certara’s upcoming earnings report date is May 11, 2026 which is in 45 days.
How were Certara’s earnings last quarter?
Certara released its earnings results on Feb 26, 2026. The company reported $0.09 earnings per share for the quarter, missing the consensus estimate of $0.112 by -$0.022.
Is Certara overvalued?
According to Wall Street analysts Certara’s price is currently Undervalued.
Does Certara pay dividends?
Certara does not currently pay dividends.
What is Certara’s EPS estimate?
Certara’s EPS estimate is 0.11.
How many shares outstanding does Certara have?
Certara has 159,139,560 shares outstanding.
What happened to Certara’s price movement after its last earnings report?
Certara reported an EPS of $0.09 in its last earnings report, missing expectations of $0.112. Following the earnings report the stock price went up 3.187%.
Which hedge fund is a major shareholder of Certara?
Currently, no hedge funds are holding shares in CERT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Certara Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.50 (55.74% Upside)
$9.50 (55.74% Upside)
Blogger Sentiment
Bullish
CERT Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 8.0%
Last 30 Days ▼ 8.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.89%
12-Months-Change
Fundamentals
Return on Equity
-0.15%
Trailing 12-Months
Asset Growth
-1.18%
Trailing 12-Months
Company Description
Certara
Certara, Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
CERT Company Deck
CERT Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mixed picture: several strong full-year achievements (9% revenue growth, software growth, improved FY adjusted EBITDA, healthy bookings and software net retention), meaningful progress in MIDD adoption and clear strategic priorities under a new CEO. However, material near-term execution and profitability challenges were disclosed — notably weaker Q4 software bookings (-6%), a Q4 net loss, declining adjusted EPS, a softer services quarter, a strategic review (and uncertainty) around the regulatory writing business, and conservative 2026 guidance (flat to +4% revenue). Management emphasized operational fixes, AI/product investment and $10M of identified cost avoidance, but 2026 is framed as a transition year while those initiatives are implemented, leaving balanced upside and downside risks.View all CERT earnings summariesCERT Stock 12 Month Forecast
Average Price Target
$9.50
▲(55.74% Upside)
Technical Analysis
Omnicell
―
Health Catalyst
―
Schrodinger
―
SOPHiA GENETICS
―
Definitive Healthcare Corp
―
Ownership Overview
2.28% Insiders
25.98% Mutual Funds
36.40% Other Institutional Investors
17.76% Public Companies and
Individual Investors